HKI-272和雷帕霉素联合治疗克服非小细胞肺癌EGFR-TKI获得性耐药

    HKI-272 and Rapamycin Combination Therapy Overcome the Acquired Resistance of EGFR-TKI in Non-Small Cell Lung Cancer

    /

    返回文章
    返回